Geoffrey Michael Glass net worth and biography

Geoffrey Glass Biography and Net Worth

Director of Avadel Pharmaceuticals

Geoffrey M. Glass has been a member of the Avadel Board of Directors since July 2018 and became Chairman of the Board in December 2018. Geoff is the founder and Chief Executive Officer of Kiniciti, a company focused on accelerating the advancement of the cell and gene therapy sector. Geoff has spent over 25 years helping lead services and therapeutic companies in the life sciences sector, including as an Operating Partner at LongueVue Capital, Chief Executive Officer of Sancilio Pharmaceuticals, and as a President at Patheon. Before Patheon, Geoff served on Valeant Pharmaceutical’s (now Bausch Health’s) executive team for nearly five years, first as Chief Information Officer and then running the company’s Asia business. Geoff received a BA in economics and political science from the University of Arizona.

What is Geoffrey Michael Glass' net worth?: The estimated net worth of Geoffrey Michael Glass is at least $609,509.12 as of December 10th, 2024. Glass owns 75,904 shares of Avadel Pharmaceuticals stock worth more than $609,509 as of April 18th. This net worth approximation does not reflect any other assets that Glass may own. Learn More about Geoffrey Michael Glass' net worth.
How do I contact Geoffrey Michael Glass?: The corporate mailing address for Glass and other Avadel Pharmaceuticals executives is 10 EARLSFORT TERRACE, DUBLIN L2, D02. Avadel Pharmaceuticals can also be reached via phone at (531) 901-5201 and via email at investors@avadel.com. Learn More on Geoffrey Michael Glass' contact information.
Has Geoffrey Michael Glass been buying or selling shares of Avadel Pharmaceuticals?: Geoffrey Michael Glass has not been actively trading shares of Avadel Pharmaceuticals in the last ninety days. Most recently, on Tuesday, December 10th, Geoffrey Michael Glass bought 20,279 shares of Avadel Pharmaceuticals stock. The stock was acquired at an average cost of $9.84 per share, with a total value of $199,545.36. Following the completion of the transaction, the director now directly owns 75,904 shares of the company's stock, valued at $746,895.36. Learn More on Geoffrey Michael Glass' trading history.
Who are Avadel Pharmaceuticals' active insiders?: Avadel Pharmaceuticals' insider roster includes Gregory Divis (CEO), Geoffrey Glass (Director), Geoffrey Glass (Director), Thomas McHugh (CFO), Linda Palczuk (Director), and Peter Thornton (Director). Learn More on Avadel Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Avadel Pharmaceuticals?: During the last twelve months, Avadel Pharmaceuticals insiders bought shares 8 times. They purchased a total of 55,579 shares worth more than $526,363.04. The most recent insider tranaction occured on January, 21st when Director Linda Palczuk bought 5,000 shares worth more than $39,650.00. Insiders at Avadel Pharmaceuticals own 4.8% of the company. Learn More about insider trades at Avadel Pharmaceuticals.
Information on this page was last updated on 1/21/2025.

Geoffrey Michael Glass Insider Trading History at Avadel Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Buy	20,279	$9.84	$199,545.36	75,904
8/10/2023	Buy	14,000	$13.40	$187,600.00	59,000
11/18/2019	Buy	20,000	$5.30	$106,000.00

Geoffrey Michael Glass Buying and Selling Activity at Avadel Pharmaceuticals

Avadel Pharmaceuticals Company Overview

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Today's Range

Now: $8.03

$7.81

$8.15

50 Day Range

MA: $8.01

$6.59

$9.09

2 Week Range

Now: $8.03

$6.38

$19.09

Volume

1,099,648 shs

Average Volume

1,220,432 shs

Market Capitalization

$775.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52